- Home
- NODK vs OCGN Comparison
NODK vs OCGN Comparison
Compare NODK & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- OCGN
- Stock Information
- Founded
- NODK 1946
- OCGN 2013
- Country
- NODK United States
- OCGN United States
- Employees
- NODK N/A
- OCGN N/A
- Industry
- NODK Property-Casualty Insurers
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NODK Finance
- OCGN Health Care
- Exchange
- NODK Nasdaq
- OCGN Nasdaq
- Market Cap
- NODK 327.3M
- OCGN 229.2M
- IPO Year
- NODK 2017
- OCGN N/A
- Fundamental
- Price
- NODK $14.66
- OCGN $0.73
- Analyst Decision
- NODK
- OCGN Strong Buy
- Analyst Count
- NODK 0
- OCGN 3
- Target Price
- NODK N/A
- OCGN $5.67
- AVG Volume (30 Days)
- NODK 14.9K
- OCGN 6.3M
- Earning Date
- NODK 11-07-2024
- OCGN 11-08-2024
- Dividend Yield
- NODK N/A
- OCGN N/A
- EPS Growth
- NODK N/A
- OCGN N/A
- EPS
- NODK N/A
- OCGN N/A
- Revenue
- NODK $391,655,000.00
- OCGN $4,700,000.00
- Revenue This Year
- NODK N/A
- OCGN N/A
- Revenue Next Year
- NODK N/A
- OCGN N/A
- P/E Ratio
- NODK N/A
- OCGN N/A
- Revenue Growth
- NODK 22.91
- OCGN N/A
- 52 Week Low
- NODK $12.71
- OCGN $0.49
- 52 Week High
- NODK $17.24
- OCGN $2.11
- Technical
- Relative Strength Index (RSI)
- NODK 31.57
- OCGN 37.06
- Support Level
- NODK $14.35
- OCGN $0.79
- Resistance Level
- NODK $15.73
- OCGN $1.00
- Average True Range (ATR)
- NODK 0.35
- OCGN 0.08
- MACD
- NODK -0.12
- OCGN -0.00
- Stochastic Oscillator
- NODK 16.32
- OCGN 13.97
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").